Table: Takeda Pharma -2025/26 parent results
05/06/2026 07:30
Jun 5 (Reuters)-
Takeda Pharmaceutical Co. Ltd.
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2026 Mar 31, 2025 Mar 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 591.60 580.36
(+1.9 pct) (-2.6 pct)
Operating 21.14 36.90
(-42.7 pct) (-23.2 pct)
Recurring 205.50 86.59
(+137.3 pct) (-69.8 pct)
Net 197.34 152.82
(+29.1 pct) (-54.9 pct)
EPS 125.29 yen 96.79 yen
EPS Diluted 125.26 yen 96.78 yen
Ann Div 200.00 yen 196.00 yen 204.00 yen
-Q2 Div 100.00 yen 98.00 yen 102.00 yen
-Q4 Div 100.00 yen 98.00 yen 102.00 yen
NOTE - Takeda Pharmaceutical Co. Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4502.T
Recent news on Takeda Pharmaceutical Co
See all newsBrief: Takeda Says Zasocitinib Significantly Outperforms Deucravacitinib In Head-To-Head Phase 3 Psoriasis Study
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Brief: U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease
Recorded 402.5 Billion Yen Additional Provision For Legal Proceedings After U.S. Jury Verdict In Antitrust Litigation
Table: Takeda Pharma -2025/26 parent results